| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.94 | -0.01 (-0.20%) | 4.03 - 6.85 | 51.0 thousand (Above Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 4.99 |
|---|---|
| Previous Close | 4.95 |
| Day's Range | 4.91 - 5.08 |
| Market Cap | 91.1M |
| Avg Volume (10 Day) | 34.6K |
| Price/Earnings (Trailing 12 Mo.) | 14.5x |
| Earnings Per Share (Trailing 12 Mo.) | 0.34 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
PR Newswire - Wednesday 05/15/2013 2:59 PM ET
Cumberland Pharmaceuticals Reports First Quarter Financial Results
PR Newswire - Thursday 05/02/2013 4:05 PM ET
Cumberland Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 2, 2013
PR Newswire - Thursday 04/25/2013 4:05 PM ET
| CPIX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -3.70% | |
| Net Income Growth (1yr) | 18.15% | |
| Total Debt/Equity | 0.05 | |
| LT Debt/Equity | 0.05 | |
| Earnings Yield | 6.90% | |
| Price/Sales | 1.87 |
| Company | Last | Change |
|---|---|---|
| DURECT Corp | 0.89 | -9.08% |
| Apricus Biosciences Inc | 3.24 | +7.28% |
| Alexza Pharmaceuticals Inc | 4.39 | -0.90% |
| Pernix Therapeutics Holdings Inc | 3.24 | -1.52% |
| NovaBay Pharmaceuticals Inc | 1.41 | +0.71% |
Data is delayed by at least 15 min.